Halozyme Therapeutics, Inc. $HALO Holdings Increased by Horizon Investment Services LLC

Horizon Investment Services LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 87.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,062 shares of the biopharmaceutical company’s stock after acquiring an additional 12,596 shares during the quarter. Horizon Investment Services LLC’s holdings in Halozyme Therapeutics were worth $1,408,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. OneDigital Investment Advisors LLC lifted its holdings in Halozyme Therapeutics by 1.7% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after acquiring an additional 175 shares during the last quarter. Penserra Capital Management LLC acquired a new position in Halozyme Therapeutics in the first quarter worth approximately $125,000. Envestnet Asset Management Inc. increased its holdings in shares of Halozyme Therapeutics by 0.4% in the first quarter. Envestnet Asset Management Inc. now owns 303,774 shares of the biopharmaceutical company’s stock valued at $19,384,000 after buying an additional 1,161 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 4.0% in the first quarter. Nisa Investment Advisors LLC now owns 5,611 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 215 shares in the last quarter. Finally, State of Michigan Retirement System lifted its position in shares of Halozyme Therapeutics by 1.0% during the 1st quarter. State of Michigan Retirement System now owns 30,438 shares of the biopharmaceutical company’s stock valued at $1,942,000 after acquiring an additional 300 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HALO has been the subject of several analyst reports. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a report on Wednesday, August 6th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price target for the company. Finally, Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Hold” and an average price target of $75.00.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $50,648,622.57. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the transaction, the director owned 44,952 shares in the company, valued at approximately $3,382,188.48. This trade represents a 4.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 108,227 shares of company stock valued at $7,779,595 over the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Up 0.1%

HALO stock opened at $68.39 on Friday. The company has a 50 day moving average of $70.76 and a two-hundred day moving average of $62.75. The company has a market cap of $8.00 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 0.35 and a beta of 1.18. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business’s revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.27 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.